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α/β or TD50 in normal tissue by immunological aspects was 
expected to improve normal tissue response in radiotherapy. 
For more precise prediction of such optimal protocols, 
treatment planning systems should be incorporated the 
biological optimization in clinical practice. 
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The Italian Center for Oncologic Hadrontherapy is up to date 
in the fifth year of its clinical activity. The total number of 
patients treated is 685 (up to November 2015). The 
treatments with carbon ions are about three times those with 
protons. An important part of treatments with carbon ions is 
directed on sarcomas, bones and soft tissue sarcomas, 
salivary glands tumours. In the table, treated patients are 
listed according to the clinical trials approved by the Italian 
Ministry of Health.  
Another substantial part of treatments regards re-irradiation 
of several pathologies, especially head and neck re-
treatments of several tumours. 
An important goal reached in the last year is the treatment 
of moving targets. Pancreatic adenocarcinomas, hepatocellar 
carcinomas and pathologies located in moving sites are 
treated through the vertical beam line with gating and 
rescanning technology. 
Treated volumes’ issue has been discussed. Many pelvic 
sarcomas and chordomas cases refer to hadrontherapy 
treatment when already reached remarkable volumes. These 
cases are subject of discussion amongst radiation oncologists 
and medical physicists. The parameters taken in 
consideration are PTV (Planning Treatment Volume) and GTV 
(Gross Tumour Volume). They are statistically evaluated to 
elaborate the best treatment strategy in term of dose and 
planning option. This issue has also economic implications. 
The treatment of major tumour volumes using mostly more 
than one field occupies the treatment room for a period of 
time equal, when not superior, to two or more patients. The 
next challenge is to improve all steps to give such treatments 
in less time. 
Most of the patients treated at CNAO are referred from 
Italian Cancer institutes but an increasing number of EU 
patients comes to Pavia through international agreements. 
In the coming period CNAO is expected to receive the 
authorization to treat all the clinical case worth to receive 
hadrontherapy treatment.  
Clinical study description Particle
Total 
number 
of 
patients 
treated
Proton radiation therapy for chordomas and chondrosarcomas of the 
skull base Protons 52
Proton therapy of spine chordoma and chondrosarcoma (amended) Protons 16
Proton therapy of intracranial meningioma Protons 24
Proton therapy of brain tumors Protons 11
Proton therapy of recurrent cervico-cephalic area tumors Protons 21
Proton boost for locally advanced cervico-cephalic area tumors Protons 28
Proton therapy of glioblastoma Protons 1
Proton re-irradiation of recurrent spine  chordoma and Protons 6
Carbon ion therapy of  adenoid cystic carcinoma of salivary glands Carbon ions 106
Carbon ion re-irradiation of recurrent pleomorphic adenomas Carbon ions 19
Carbon ion re-irradiation of recurrent rectal cancer Carbon ions 8
Carbon ion radiotherapy for bone and soft tissue sarcoma of cervico-
cephalic area Carbon ions 94
Carbon ion radiotherapy for bone and soft tissue sarcoma of trunk Carbon ions 119
Carbon ion  therapy of recurrent cervico-cephalic area tumors Carbon ions 90
Carbon ion therapy of malignant melanoma of the mucous of the 
upper aerodigestive tract Carbon ions 14
Carbon ion therapy for high risk prostate cancer Carbon ions 9
Carbon ion therapy of primary and secondary orbital tumors Carbon ions 13
Carbon ion therapy for pancreatic cancers Carbon ions 11
Carbon ions therapy of primary malignant tumors of the liver Carbon ions 4
Carbon ion re-irradiation of recurrent spinal chordoma and Carbon ions 7
Protons and/or carbon ion integrated radiotherapy for poor prognosis 
in patients with inoperable sinonasal tumor
Protons/ Carbon 
ions 4
Other - 28
685  
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Molecular imaging provides unique information on the tumor 
phenotype (i.e. tumor cells and tumor microenvironment), 
influencing treatment decisions and adaptation of therapy by 
early prediction of treatment outcome. With the increasing 
importance of systemic targeted therapies and of high 
precision external beam radiotherapy, interrogating tumor 
characteristics before and during therapy becomes 
increasingly important. 
Key features like tumor metabolism, proliferation and 
protein synthesis can be depicted by the well-known 
radiopharmaceuticals FDG, FLT and e.g. FAZA, respectively. 
Furthermore, imaging receptor expression on tumor cells 
with e.g. radiolabeled antibodies and peptides can provide 
information on the presence, heterogeneity, accessibility, 
and modulation of these receptors for targeted therapies. 
Thirdly, small molecules like TKI may radiolabeled providing 
similar insight in tumor pathophysiology allowing better 
selection of patients likely to respond to treatment. A 
distinct form of theranostics utilizes targeting molecules, 
radiolabeled with an gamma or positron emission for imaging 
selecting patients for treatment with the same molecule, 
now radiolabeled with a beta-emitter. 
In conclusion, various applications of theranostics provide 
crucial insight in tumor biology, the choice and adaptation of 
treatment, allowing better selection of treatment to achieve 
better outcomes for cancer patients.  
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Comparative evaluation of the in vitro the comet assay for 
the detection of genotoxic effects of 60 MeV protons and 
X-ray radiation  
